AABB released a graphic summary of findings from the 2021 AABB member hospital transfusion services survey conducted to evaluate practices in the use of COVID-19 convalescent plasma (CCP).
A total of 200 hospitals from 43 states completed the survey, conducted January 4 to 11. Most of the hospitals reported transfusing CCP in the range of 0-24 units. Furthermore, 26 percent of the hospitals reported increasing numbers of CCP transfusions, while 28 percent reported “about the same” usage and 34 percent reported a declining trend of CCP transfusion. With regard to supply, 28.7 percent reported delays in obtaining CCP units, an upward trend that began the week of Oct. 26, 2020. Delays in group AB and B CCP units are most reported.
Based on the responses to this survey, the average CCP dose-to-patient ratio among AABB member hospitals is estimated to be 1.3:1. Since a majority of the hospitals reported that the use of CCP was at the discretion of the individual ordering physician/team, variability in the estimate can be expected in studies conducted at a different time and with a different survey population.
